Article Text

Download PDFPDF
CASE REPORT
Cyclooxygenase-2 inhibitor-induced acute interstitial nephritis
  1. Brittany Albrecht1,
  2. Shelley Giebel2,
  3. Michelle McCarron3,
  4. Bhanu Prasad4
  1. 1College of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada
  2. 2College of Nursing, University of Regina, Regina, Saskatchewan, Canada
  3. 3Research and Performance Support, Regina Qu'Appelle Health Region, Regina, Saskatchewan, Canada
  4. 4Nephrology, Regina General Hospital, Regina, Saskatchewan, Canada
  1. Correspondence to Dr Bhanu Prasad, bprasad{at}sasktel.net

Summary

A 64-year-old female patient presented to the emergency department with a 3-week history of persistent nausea and vomiting. Her serum creatine prior to admission was 118 µmol/L and on presentation was elevated to 420 µmol/L. On clinical history, she indicated that 3 weeks prior, she had been initiated on a cyclooygenase-2 (COX-2) inhibitor, celecoxib, for her osteoarthritis of her knees. Renal biopsy confirmed the diagnosis of acute interstitial nephritis (AIN). Celecoxib was discontinued and the patient’s renal function improved to a discharge creatine of 205–220 µmol/L. Nine months later, her creatine had decreased to 195 µmol/L and she was initiated on tapering doses of prednisone therapy for 4 months, after which time her creatine had improved further to 143 µmol/L. She was later transitioned to mycophenolatemofetil for 9 months and her creatine improved to 110 µmol/L. This report provides further evidence that COX-2 inhibitors are associated with AIN.

  • Acute renal failure
  • Chronic renal failure

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors BP, BA and SG wrote the initial manuscript. BP revised and edited the manuscript. MM did the final critical revision.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.